​​​Copyright © 2016 RiboCor, Inc. All rights reserved.     RiboCor, Inc. • 7077 Northland Circle North • Suite 100 • Minneapolis • MN • 55428 • Phone: 866-246-3637 • Email: Info@ribocor.com

*Viacell, LLC Board of Directors

John H. Broadbent, Jr. • Chairman *
Mr. Broadbent was a co-founder of Arrow International, Inc., a leading developer, manufacturer and world-wide marketer of a broad range of clinically advanced, disposable catheters and related products for critical and cardiac care. Mr. Broadbent was Chief Financial Officer, Vice-President — Finance and Treasurer of Arrow from its founding in 1975 until he retired in 1998. Mr. Broadbent served as a Director of Arrow until its sale to Teleflex in 2007. Mr. Broadbent earned a bachelor’s degree in chemical engineering from Rensselaer Polytechnic Institute and a MBA from Harvard University. He is an investor in several privately held companies in the healthcare field.

Howard S. Weintraub, PhD.
Dr. Weintraub is a principal of the Landfall Therapeutics Consulting Group, LLC, which provides strategic and technical consulting for pharmaceutical and medical device companies. Until his retirement in 2003, Dr. Weintraub was Vice President, R & D Corporate Staff for C.R. Bard. In this role, Dr. Weintraub was responsible for Bard’s business development activities. Dr. Weintraub received a B.Sc. in Pharmacy from Columbia before completing a Ph.D. in Biopharmaceutics from the State University of New York, Buffalo. He has over 30 years’ experience in pharmaceutical research and development and is chairman of Company’s compensation committee.

H.B. “Bud” Hayden *
Mr. Hayden is founder and former principal shareholder of Metro-quip, Inc., a Minnesota-based Midwest distributor of construction equipment. Mr. Hayden, a well-known Twin Cities entrepreneur, joined the Bioenergy board of directors in 1996. He served as the companys interim CEO from May 2007 through July 2008. Mr. Hayden earned a bachelors degree in mechanical engineering from the Sibley School of Mechanical Engineering, College of Engineering, Cornell University.

Michael Graves
Mr. Graves was President and Chief Executive Officer of Paddock Laboratories, a developer, manufacturer and marketer of OTC and specialty brand and generic prescription products from 2007 to July 2011. Mr. Graves grew the sales of the company from $65 million to over $220 million prior to its acquisition by Perrigo for $540 million dollars. Prior to his position with Paddock Laboratories Mr. Graves was President of the Generic Division of Par Pharmaceutical, at which time, was the fifth largest marketer of generic products in the United States. Mr. Graves has also held executive positions at two of the country’s largest pharmaceutical distributors. Mr. Graves received a BS from the State University of New York, Buffalo and has over 18 years of diverse pharmaceutical experience.

Danielle Johnson
Ms. Johnson currently holds the position of Chief Operating Officer at Florida Hospital Fish Memorial. Florida Hospital Fish Memorial is a private, not-for-profit hospital. The hospital is a 175-bed acute care facility providing adult care primarily to residents of southwest Volusia County, Florida. The hospital employs approximately 1000 staff and has 220 physician on staff. The major clinical areas of service include: Anatomic Pathology, Anesthesiology, Cardiology, Cardiac Diagnostic Catheterization, Cytology, Emergency Medicine, Gastroenterology, General Surgery, Geriatrics, Gynecology, Infectious Disease, Internal Medicine, Clinical Laboratory, Oncology, Ophthalmology, Orthopedic Surgery, Otolaryngology, Plastic Surgery, Podiatry, Diagnostic Radiology, Interventional Radiology and Nuclear Medicine, Radiation Oncology, Rehabilitation Medicine, Thoracic, Urology, Vascular Surgery and Wound Care.

​Raj Khankari, PhD., MBA *

Dr. Khankari joined RiboCor, Inc. in August, 2008 and was elected to the Board of Directors of RiboCor and Viacell in September, 2008. Dr. Khankari is responsible for the overall direction and performance of the Company. Prior to RiboCor, Dr. Khankari was the General Manager and Vice-President of Worldwide Drug Technologies for CIMA LABS INC., a Cephalon company, where he was responsible for the performance and growth of the drug delivery business for Cephalon. The holder of 15 patents and author of several peer-reviewed journal articles, Dr. Khankari has more than 23 years of experience in developing and successfully introducing pharmaceutical products to the market. His experience also includes numerous technology licensing transactions, both domestic and international. While at RiboCor, Dr. Khankari successfully licensed the Corvalen product and divested the bulk ingredient Ribose business. Dr. Khankari holds Ph.D. and MBA degrees from the University of Minnesota, an MS degree from the University of Cincinnati, and an M.Pharm. and a B.Pharm. from India.

Daniel Ericson, PhD *

Dr. Daniel Ericson invented and developed Viacell Technology.  Dr. Ericson has over 30 years of experience in developing blood biomaterials, hematology research and other biologics. Dr. Ericson is also a President of SUBC, Inc.  He has developed and patented various technologies, engineered prototypes, and transferred the technologies to Boston Scientific, Medtronic, Placor and GF Fluidics. Dr. Ericson has licensed an implantable device technology to Cook Medical.  He is a holder of over 30 patents. Dr. Ericson holds a Ph.D. in Biomedical engineering from University of Minnesota.

Board of Directors